07:00 , Mar 9, 2015 |  BioCentury  |  Finance

Malin's fast start

A little more than a year after Perrigo Co. acquired Elan Corp. plc for $9.2 billion, a handful of ex-Elan executives, including former CEO Kelly Martin, have launched Malin Corp. plc, a new life sciences...
07:00 , Mar 31, 2014 |  BioCentury  |  Finance

Banker tracks

Banker tracks Former ABN AMRO executive directors Maurice Laudy and Machiel van Oostveen launched healthcare advisory firm Saola Healthcare Partners. Saola's focus includes life sciences, medtech, diagnostics, and healthcare services and distribution. Private equity tracks Thomas Lips joined...
07:00 , Oct 7, 2013 |  BioCentury  |  Finance

Banker tracks

Banker tracks Maurice Laudy and Machiel Van Oostveen departed from the healthcare sector of ABN AMRO to start an independent healthcare advisory firm. Laudy had been an executive director and head of healthcare, while Van Oostveen...
07:00 , May 7, 2012 |  BioCentury  |  Finance

Back together again

Back together again Dutch bank ABN AMRO Bank N.V. has reacquired the M&A, advisory, equity brokerage and capital structuring capabilities in the Netherlands that it sold in 2007 to a consortium led by the Royal Bank...
08:00 , Dec 12, 2011 |  BioCentury  |  Finance

Third time around

Forbion Capital Partners has gone back to the LP well for the third time to continue to invest in portfolio companies from its first fund. Forbion's first fund closed in 2006 at about €200 million ($264...
07:00 , Jun 27, 2011 |  BC Week In Review  |  Financial News

Agendia postpones IPO

Agendia B.V., Amsterdam, the Netherlands   Business: Diagnostic, Microarrays   Date announced: 6/20/11   Type: IPO   Underwriters: ABN AMRO; ING Bank; Kempen & Co.; KBC   Note: Agendia postponed its IPO on NYSE Euronext in Amsterdam citing market conditions....
07:00 , Jun 27, 2011 |  BioCentury  |  Finance

Off the agenda

Off the agenda Molecular diagnostics play Agendia B.V. was slated for an IPO last week, but instead it pulled the offering, citing the volatile stock market. Earlier this month, the company said it expected to start trading...
07:00 , Jun 27, 2011 |  BioCentury  |  Finance

What to do with $101M

Last week's $101M tranched series B round for oncology play Tesaro Inc. is expected to get the company to NDA submission for its lead candidate, in-license up to two additional compounds and advance a preclinical...
07:00 , Jun 13, 2011 |  BC Week In Review  |  Financial News

Agendia amends IPO

Agendia B.V., Amsterdam, the Netherlands   Business: Diagnostic, Microarrays   Date announced: 6/6/11   Type: IPO   To be raised: Up to €75 million ($109.6 million)   Shares: 4.6 million   Price: €16.36- €19.15   Underwriters: ABN AMRO; ING Bank; Kempen &...
07:00 , Jun 13, 2011 |  BioCentury  |  Finance

Agendia's agenda

Molecular diagnostics play Agendia B.V. expects to start trading on June 21 on NYSE Euronext in Amsterdam. It hopes to raise up to €75 million ($109.6 million) through the sale of up to 4.6 million...